Please login to the form below
Ebola disease
This page shows the latest Ebola disease news and features for those working in and with pharma, biotech and healthcare.
AbbVie, Amgen and Takeda team up for joint COVID-19 trial
Together, experts across our companies and industry can accelerate trials with promising, well-understood therapies that upon investigation, may show efficacy in this devastating disease," he added. ... This includes Gilead’s investigational antiviral
Latest news
-
UPDATED: Gilead drops remdesivir’s orphan drug designation
Calling COVID-19 a rare disease mocks people’s suffering and exploits a loophole in the law to profiteer off a deadly pandemic,” it added. ... Remdesivir, originally developed as a treatment for Ebola virus disease, has been in the global spotlight
-
Clinical trial of Gilead’s coronavirus hopeful remdesivir begins in US
Prior to the novel coronavirus outbreak, Gilead was evaluating remdesivir as a treatment for Ebola virus disease, but since the drug has also shown promise against other types of coronavirus – namely
-
Merck’s Ebola vaccine wins approval in four African countries
Merck became the first drug developer to win approval for an Ebola vaccine last year, from both the US Food and Drug Administration and the European Medicines Agency. ... The DRC is currently experiencing an outbreak of Ebola, with more than 2, 200 live
-
China’s BrightGene successfully copies Gilead’s coronavirus hopeful remdesivir
cases. In an attempt to stop the spread of the disease, researchers as well as Chinese health authorities have been testing a number of experimental therapies against COVID-19. ... The one with the most potential – so far – has been antiviral drug
-
The year in review
Speaking of response and crisis, 2019 also reminded us that Ebola is still around. ... As of September, a total of 3, 091 Ebola virus disease cases were reported, including 2, 980 confirmed and 111 probable cases, of which 2, 074 patients died.
More from news
Approximately 1 fully matching, plus 13 partially matching documents found.
Latest Intelligence
-
As COVID-19 takes over the world, biopharma fights back
Prior to the coronavirus outbreak, Gilead had primarily been focused on testing remdesivir’s potential in Ebola virus disease, although the antiviral also demonstrated promise in other coronaviruses, including severe acute ... Infectious disease expert
-
Communicating in a crisis
For example about 600, 000 people die of heart disease in the US each year, according to the Centers for Disease Control and Prevention, yet Ebola has taken the headlines. ... But for Lund, when discussing a united front to contain and eradicate
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
-
B2B media account director
-
Competitive salary
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- First trial of a vaccine against Alzheimer’s launches
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- Novo Nordisk growth takes a hit with China deal
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Merck enters agreement with Hanmi for investigational NASH drug
- Booster plans expanded to combat Omicron
- US regulators set to approve oral antiviral against COVID-19
- What does the future hold for Light-chain Amyloidosis?
- As HCPs Increasingly Expect Personalized Engagement, Pharmas Turn to Modular Intelligent Content. How Does This Work?
- COVID-19 vaccines against Omicron may be fast-tracked
- BMS’ new JAK inhibitor enters regulatory pathways
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Biogen hands out $120m upfront for Remedy stroke drug
- Pfizer's 2021 revenue predictions soar to $82bn
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Pfizer fined $60m for bribing doctors to win business
- Synairgen’s SNG001 advances into phase 3 COVID-19 trial
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...
Latest intelligence
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
